Dolomite’s Fluidic Factory recognized with R&D 100 Award
24 November 2016 | By Dolomite
Dolomite is celebrating the success of its Fluidic Factory 3D printer in the ‘Processing and Prototyping’ category this year’s R&D 100 Awards...
List view / Grid view
News
AstraZeneca head and neck cancer trials resume as FDA lifts clinical hold
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume shortly....
Linkam launch the Optical DSC450 for the simultaneous visualisation of thermal transition experiments for improved materials characterisation
23 November 2016 | By Linkam Scientific Instruments Limited
Linkam Scientific Instruments, announce the launch of their Optical DSC450 which enables simultaneous visualization of thermal processes...
ViiV Healthcare to evaluate injectable HIV treatment
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
Hikma and Vectura to develop and license generic salmeterol for US market
22 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Generic salmeterol is a generic long acting beta‐agonists for the treatment of asthma and COPD, delivered using Vectura’s proprietary dry powder inhalation...
Bellicum recommended for $16.9 million Texan cancer research award
22 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The Institute of Texas award would fund a 3 year global clinical program of clinical trials for adult and paediatric patients acute myeloid leukaemia...
FPS still looks ahead
21 November 2016 | By F.P.S. Food and Pharma Systems Srl
FPS is pleased to announce the enlargement of his production plant...
NICE recommends faecal immunochemical tests for colorectal cancer
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
FITs are considered to be accurate because unlike other tests, they use immunochemical detection methods that are specific to human haemoglobin...
Boehringer Ingelheim’s bevacizumab biosimilar demonstrates bioequivalence
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BI 695502, a bevacizumab biosimilar candidate to Avastin, is a monoclonal antibody that may slow or stop the growth of certain tumour types by preventing...
Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab...
Price discount helps give green light for Roche’s breast cancer drug
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision...
UCB and Amgen’s Osteoporosis study shows bone mineral density gains
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The BRIDGE study involved 245 men with osteoporosis randomised 2:1 to receive either 210 mg romosozumab or placebo subcutaneously once monthly for 1 year...
Novartis’ acute myeloid leukaemia drug granted FDA priority review
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA granted priority review to the PKC412 (midostaurin) new drug application as treatment for acute myeloid leukaemia...
Tackling resistance: 3/4 Brits support mandatory test before antibiotic prescriptions
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Around three-quarters (74%) of people believe that a positive test for bacterial infection should be compulsory before being able to access antibiotics...
AbbVie’s Hep C drug achieves high SVR rates after just 8 weeks of treatment
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load...
